Form 4: Guardant Health Director Converts RSUs to Common Stock

Guardant Health Director Manuel Hidalgo Medina converted 232 Restricted Stock Units into common stock, increasing his direct common stock holdings to 3,016 shares.

Summary

• Director Manuel Hidalgo Medina converted 232 Restricted Stock Units (RSUs) into common stock on August 17, 2025.
• This transaction increased his direct beneficial ownership of Guardant Health common stock to 3,016 shares.
• The RSUs were originally granted on July 17, 2024, with 25% vesting on the one-year anniversary of the grant date (July 17, 2025), and the remaining 75% vesting monthly over the subsequent three-year period.
• Following this conversion, Medina retains 8,121 unvested Restricted Stock Units.

Sentiment

Score: 6

Explanation: The conversion of Restricted Stock Units into common stock by a director is a routine compensation event, indicating continued alignment of interests with shareholders. It's not a direct purchase, but it increases the director's direct equity stake, which is mildly positive.

Positives

• Director Manuel Hidalgo Medina increased his direct beneficial ownership of common stock by 232 shares, now holding a total of 3,016 shares, which aligns his interests with shareholders.

Future Outlook

The remaining 75% of the Restricted Stock Units granted on July 17, 2024, are scheduled to vest monthly over the three-year period following July 17, 2025.

Industry Context

This filing is a routine insider transaction report and does not provide specific industry context or trends.

Stakeholder Impact

• Shareholders: The increase in direct common stock ownership by a director may be viewed as a positive signal of continued confidence in the company's future.

Next Steps

• Remaining 75% of the original RSU grant will continue to vest monthly over the next three years from July 17, 2025.

Key Dates

Recommendation

The filing details a routine conversion of Restricted Stock Units by a director into common stock, which is a standard compensation event and does not provide new fundamental information to alter an investment thesis. While it increases the director's direct equity stake, it's not a discretionary open-market purchase that would typically warrant a change in investment recommendation.

Keywords

Guardant Health, GH, SEC Form 4, insider transaction, RSU conversion, stock ownership, director